CERO — CERo Therapeutics Holdings Cashflow Statement
0.000.00%
- $4.78m
- $2.00m
Annual cashflow statement for CERo Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -11.8 | -7.29 | -8.3 |
Depreciation | |||
Non-Cash Items | 0.941 | 0.499 | -6.89 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | -1.3 | 0.54 | 1.84 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Change in Other Liabilities | |||
Cash from Operating Activities | -11.7 | -5.79 | -12.9 |
Capital Expenditures | -0.694 | 0 | — |
Purchase of Fixed Assets | |||
Cash from Investing Activities | -0.694 | 0 | — |
Financing Cash Flow Items | 0 | -0.039 | -0.02 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0.006 | 0.572 | 13.7 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -12.4 | -5.22 | 0.812 |